UBS Maintains Buy on DexCom, Lowers Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy maintains a Buy rating on DexCom (NASDAQ:DXCM) but lowers the price target from $163 to $95.
July 26, 2024 | 4:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS analyst Danielle Antalffy maintains a Buy rating on DexCom but lowers the price target from $163 to $95.
The lowered price target from $163 to $95 suggests a significant reduction in expected valuation, which could negatively impact investor sentiment in the short term despite the maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100